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ABSTRACT
Objectives: The aim of our study was to compare serum irisin concentrations in pregnant women with and without ges-
tational diabetes mellitus (GDM).
Material and methods: This study was performed at the Tertiary Care Center, Department of Obstetrics and Gynecol-
ogy, between January 2014 and April 2014. A total of 45 pregnant women with GDM (diabetes group) and 41 BMI- and 
age-matched healthy pregnant women (control group) were recruited. Maternal serum irisin levels were measured by 
enzyme-linked immunosorbent assay kit at 24–28 weeks of gestation. An association between maternal serum irisin lev-
els and metabolic parameters was analyzed. Body mass index, serum levels of glucose, insulin and irisin were tested and 
analyzed in the study group and controls.
Results: Pregnant women with GDM had significantly higher fasting plasma glucose (p = 0.001), first-hour OGTT glucose 
(p = 0.001), second-hour OGTT glucose (p = 0.001), and fasting insulin (p = 0.045) levels as compared to controls. Serum irisin 
levels were 1.04 ± 0.3 and 1.3 ± 0.2 in pregnant women with GDM and healthy pregnant controls, respectively (p = 0.001). 
Correlation analysis between irisin levels and anthropometric and biochemical parameters in patients with gestational 
diabetes revealed that none of the investigated parameters correlated with serum irisin level.
Conclusions: Our results suggest that serum irisin levels might be introduced as a novel marker for GDM, with decreased 
levels of irisin being indicative of GDM.
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INTRODUCTION
Gestational diabetes mellitus (GDM) is defined as a car-
bohydrate intolerance of varying severity, with onset or 
first recognition during pregnancy. GDM prevalence may 
range from 1% to 14% of all pregnancies, depending on 
the studied population and the diagnostic test employed 
[1]. The pathogenesis of GDM is multifactorial and may 
include genetic and environmental factors, but the exact 
mechanism remains to be fully elucidated [2]. Women with 
GDM are at increased risk of perinatal morbidity, impaired 
glucose tolerance, and type 2 diabetes in the years after 
pregnancy. Children born to women with GDM are also 
more likely to be obese, have impaired glucose tolerance 
and diabetes in childhood and early adulthood [3].
In the past few years, dysregulation of various adi-
pocyte- and hepatocyte-derived factors (including adi-
ponectin, leptin, fibroblast growth factor-21, and adipocyte 
fatty acid-binding protein) has been reported to mediate 
insulin resistance and proinflammatory effects in GDM [4, 
5]. Moreover, myocyte-secreted proteins, in addition to 
adipokines and hepatokines, generated renewed interest 
in the field of metabolic diseases most recently. In this con-
text, the fundamental study of Boström et al., introduced 
the myokine irisin as an exercise-inducible secreted factor 
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that improves glucose tolerance and increases energy ex-
penditure in mice [6].
So far, data about irisin in humans have been insuffi-
cient to evaluate its metabolic effects and association with 
metabolic disease. Irisin is an anti-diabetic hormone that 
regulates the glucose metabolism and energy consumption 
via converting white to brown adipose tissue [7]. Reports on 
irisin regulation in GDM and pregnancy are scant.
OBJECTIVE
To the best of our knowledge, only five studies on the 
association between irisin and GDM have been reported 
in the literature [8–12]. In light of the conflicting results of 
these studies, we also wished to investigate this topic. The 
aim of our study was to compare serum irisin concentra-
tions between pregnant women with GDM and healthy 
pregnant women. Serum irisin levels may have a potential 
as a novel marker for diagnosis and follow-up of gestational 
diabetes mellitus.
MATERIAL AND METHODS
This study was approved by the Local Ethics Committee 
(no: 2014/64) and written informed consent was obtained 
from all subjects. A total of 45 pregnant women with ges-
tational diabetes mellitus (diabetes group) and 41 BMI- and 
age-matched healthy pregnant women (control group), ad-
mitted to our tertiary care center, Department of Obstetrics 
and Gynecology between January 2014 and April 2014, were 
recruited for this case-control study. Hypertensive pregnant 
subjects, patients > 40 years of age, and pregnant women 
with BMI > 30 were excluded from the study. 
All participants underwent a thorough clinical examina-
tion. The diagnosis of GDM was based on the International 
Diabetes in Pregnancy Consensus Group criteria [13]. The 
diagnosis of GDM was made according to the HAPO criteria, 
when one of the following plasma glucose values in the 
oral glucose tolerance test (OGTT) was met or exceeded: 
fasting plasma glucose 92 mg/dL (5.1 mmol/L); 1-h plasma 
glucose 180 mg/dL (10.0 mmol/L); and 2-h plasma glu-
cose 153 mg/dL (8.5 mmol/L). Body mass index was deter-
mined as weight divided by squared height. Irisin serum 
concentrations were determined with an enzyme-linked 
immunosorbent assay (Human Irisin ELISA kit, MyBiosource 
Inc, San Diego, CA, USA) according to the manufacturer’s 
instructions at 24–28 gestational weeks. Fasting serum 
irisin level was measured 3 days after the OGTT test. Fur-
thermore, fasting insulin was determined with a two-site 
chemiluminescent enzyme immunometric assay. Moreo-
ver, glycosylated hemoglobin A1c (HbA1c) was measured. 
The association between maternal serum irisin levels and 
metabolic parameters was analyzed.
Statistical analysis
Data were analyzed using the Statistical Package for 
Social Sciences 19.0 for Windows (SPSS Inc., Chicago, IL). 
Data were tested for normality with the Shapiro-Wilk test. 
Data with a normal distribution (blood pressure values, 
serum glucose, insulin, and irisin levels) were compared 
with the student’s t test (correlation coefficients were cal-
culated with Pearson’s r), and expressed as mean ± SD. Data 
without normal distribution (age, BMI) were compared with 
the Mann-Whitney-U test, and expressed as median (inter-
quartile range). The p-value of < 0.05 was considered as 
statistically significant. 
RESULTS
A total of 84 pregnant women met the eligibility criteria 
for the study. The diabetes group included 45 pregnant 
women with gestational diabetes mellitus and the control 
group included 41 of their age-matched healthy pregnant 
peers. 
Both groups did not differ in terms of age (p = 0.759), 
BMI (p = 0.743), weight gain (p = 0.354), systolic (p = 0.665), 
and diastolic blood pressure (p = 0.789). Pregnant women 
with GDM had significantly higher fasting plasma glucose 
(p = 0.001), first-hour OGTT glucose level (p = 0.001), sec-
ond-hour OGTT glucose level (p = 0.001), and fasting insulin 
(p = 0.045) levels as compared to the control group. Serum 
irisin level was 1.04 ± 0.3 in pregnant women with GDM, and 
1.3 ± 0.2 in controls (p = 0.001) (Figure 1, Table 1).
Correlation analysis between irisin levels and anthro-
pometric and biochemical parameters in patients with 
gestational diabetes revealed none of the parameters to 
be correlated with serum irisin level (Table 2).
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Figure 1. Serum irisin level  in pregnant women with GDM and in 
controls
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DISCUSSION
In this study, we attempted to compare serum irisin 
concentrations between pregnant women with GDM and 
age-matched healthy pregnant women, and found that 
maternal serum irisin levels were significantly lower in preg-
nant women with GDM as compared to controls. Recently, 
a muscle-secreted peptide named irisin was identified and 
suggested to play an important role in improving obesity 
and glucose homeostasis [14]. Irisin has attracted consider-
able attention because it has been claimed to have thera-
peutic potential for obesity and diabetes and to improve 
life expectancy [15].
A positive association between circulating irisin and 
markers of glucose intolerance was detected by two in-
dependent studies in non-pregnant subjects [16, 17]. Huh 
et al., showed that irisin correlated positively with fasting 
glucose in 117 healthy non-pregnant women [16]. Stengel 
et al., demonstrated that circulating plasma irisin is posi-
tively associated with fasting insulin level [17]. In contrast, 
Moreno-Navarrete et al., showed that the expression of the 
irisin encoding gene FNDC5 in adipose and muscle tissue 
is reduced in obese and diabetic patients as compared to 
non-obese subjects [18]. Furthermore, irisin serum levels 
are lower in Chinese patients with new-onset T2DM as com-
pared to non-diabetic subjects [18]. Two previous reports 
observed a decreased level of circulating irisin in patients 
with type 2 diabetes as compared to normal glucose toler-
ance subjects [18–20]. All things considered, the current and 
the previous results support the hypothesis that increased 
circulating irisin is an adaptive response to compensate 
for the decreasing insulin sensitivity and disturbances in 
metabolism associated with obesity [21]. Although irisin 
is also secreted by adipose tissue, the reduced irisin levels 
displayed in type 2 diabetes may be due to the decrease of 
body fat stores in uncontrolled insulin-deficient diabetes as 
is the case with leptin [22]. In our study, serum irisin level 
was lower in pregnant women with GDM as compared to 
healthy pregnant women.
The relationship between irisin and markers of energy 
metabolism has been explored earlier by other authors. Simi-
larly to our results, Timmons et al., reported that irisin was 
not related to markers of energy metabolism including BMI, 
fasting insulin, and fasting glucose [23]. However, Huh et al., 
found that circulating irisin concentrations were positively 
correlated with BMI and fasting glucose [16]. We are of the 
opinion that these discrepancies may be explained by the 
differences in their study population. Timmon et al., analyzed 
the association between myocyte irisin and markers of en-
ergy metabolism in a diabetic population, while Huh et al., 
conducted their study in healthy women [23]. Kuzmicki et al., 
stated that serum irisin concentration increased remarkably 
in pregnant women, but this increase was significantly less 
obvious in patients with GDM [9]. In our study, a correlation 
Table 1. Comparison of clinical and biochemical results between the patients with gestational diabetes mellitus and control subjects
Variable Diabetes group  (n = 45)
Control group  
(n = 41) p value
Age (years) 30 (26–34) 29 (26–33) 0.759
BMI at the time of OGTT [kg/m2] 28.6 (24.2–31.6) 26.8 (23.6–31.5) 0.743
Weight gain [kg] 7.4 ± 3.9 8.2 ± 4 0.354
Systolic blood pressure[mm Hg] 114.3 ± 12.5 113 ± 14.5 0.665
Diastolic blood pressure [mm Hg] 70.3 ± 9.1 70.8 ± 8.9 0.789
Fasting plasma glucose [mg/dL] 94.3 ± 10.2 79.9 ± 4.8 0.001*
OGTT — 1st hour plasma glucose [mg/dL] 190.2 ± 29.8 117.1 ± 20.1 0.001*
OGTT — 2nd hour plasma glucose [mg/dL] 142.9 ± 37.2 101.2 ± 14.6 0.001*
Fasting insulin [μIU/mL] 9.2 ± 3.7 7.5 ± 3.9 0.045*
Irisin 1.04 ± 0.3 1.3 ± 0.2 0.001*
*Statistically significant. BMI — body mass index; OGTT — oral glucose tolerance test
Table 2. The correlation between irisin levels and anthropometric 
and biochemical parameters in patients with gestastional diabetes 
Parameter r p
Age –0.26 0.071
Weight at the time of OGTT –0.030 0.844
BMI at the time of OGTT –0.038 0.801
Weight gain 0.098 0.513
Systolic blood pressure 0.045 0.766
Diastolic blood pressure 0.196 0.186
Fasting plasma glucose 0.084 0.577
OGTT — 1st hour plasma glucose 0.022 0.882
OGTT — 2nd hour plasma glucose –0.132 0.378
Fasting insulin –0.141 0.344
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analysis of irisin levels and anthropometric and biochemical 
parameters in patients with gestational diabetes revealed 
that none of the parameters correlated with serum irisin level.
Limitations of our study included a relatively small sam-
ple size, and lack of definitive selection criteria for the BMI. 
Although BMI level was not different between the groups, 
we had patients with the BMI below 25 or above 30. Also, we 
did not include serum level of the lipid profile due to the lack 
of data in most of the investigated patients. In light of these 
restrictions, associations should be interpreted with caution.
CONCLUSIONS
Maternal serum irisin levels were significantly lower in 
pregnant women with GDM as compared to the control 
group. This result suggests that serum irisin levels might be 
introduced as a novel marker for GDM and decreased levels 
of irisin might be indicative of GDM. Further randomized, 
prospective, controlled trials on larger series are necessary 
to make more precise interpretations. 
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